Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"AlivaMab","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AlivaMab","sponsor":"Ablexis","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"}]

Find Clinical Drug Pipeline Developments & Deals by AlivaMab

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            New strains of AlivaMab XKL Mice offered by Ablexis that further expand the molecular and epitope diversity of the immune response to promote even broader responses against the increasingly complex types of antigens at the cutting edge of antibody drug discovery.

            Lead Product(s): Antibody-based Therapeutics

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Recipient: Ablexis

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The programs will leverage the ADS discovery platform, which includes a suite of different immunization technologies that address challenging targets such as G-protein-coupled-receptors and high homology targets.

            Lead Product(s): Antibody-based Therapeutic

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY